These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31957010)

  • 1. Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.
    Gibiansky L; Ravva P; Parrott NJ; Bhardwaj R; Zwanziger E; Grimsey P; Clinch B; Sturm S
    Clin Pharmacol Ther; 2020 Jul; 108(1):126-135. PubMed ID: 31957010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
    Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
    Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
    Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.
    Kamal MA; Acosta EP; Kimberlin DW; Gibiansky L; Jester P; Niranjan V; Rath B; Clinch B; Sánchez PJ; Ampofo K; Whitley R; Rayner CR
    Clin Pharmacol Ther; 2014 Sep; 96(3):380-9. PubMed ID: 24865390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir dosing in premature infants.
    McPherson C; Warner B; Hunstad DA; Elward A; Acosta EP
    J Infect Dis; 2012 Sep; 206(6):847-50. PubMed ID: 22807525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.
    Standing JF; Nika A; Tsagris V; Kapetanakis I; Maltezou HC; Kafetzis DA; Tsolia MN
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3833-40. PubMed ID: 22564835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.
    Gibiansky L; Giraudon M; Rayner CR; Brennan BJ; Subramoney V; Robson R; Kamal MA
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):225-36. PubMed ID: 25821064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.
    Pillai VC; Han K; Beigi RH; Hankins GD; Clark S; Hebert MF; Easterling TR; Zajicek A; Ren Z; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2015 Nov; 80(5):1042-50. PubMed ID: 26040405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
    Kamal MA; Lien KY; Robson R; Subramoney V; Clinch B; Rayner CR; Gibiansky L
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6774-81. PubMed ID: 26282419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.
    Chairat K; Jittamala P; Hanpithakpong W; Day NP; White NJ; Pukrittayakamee S; Tarning J
    Br J Clin Pharmacol; 2016 Jun; 81(6):1103-12. PubMed ID: 26810861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
    Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
    Chen Y; Ke M; Xu J; Lin C
    AAPS PharmSciTech; 2020 Mar; 21(3):98. PubMed ID: 32128656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population.
    Huang H; Wang J; Li Q; Duan J; Yao Q; Zheng Q; Wang J; Wu D; Zhou Q; Tian Y; Zhang J
    J Matern Fetal Neonatal Med; 2017 Jun; 30(11):1288-1292. PubMed ID: 27426925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.
    Anderson BJ; Allegaert K; Van den Anker JN; Cossey V; Holford NH
    Br J Clin Pharmacol; 2007 Jan; 63(1):75-84. PubMed ID: 16869817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.
    Maltezou HC; Drakoulis N; Siahanidou T; Karalis V; Zervaki E; Dotsikas Y; Loukas YL; Theodoridou M
    Pediatr Infect Dis J; 2012 May; 31(5):527-9. PubMed ID: 22209917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
    Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
    Hu ZY; Edginton AN; Laizure SC; Parker RB
    Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.